Fenwick represented Playground Global, a venture capital firm based in Palo Alto, CA, in the intellectual property due diligence aspect of its seed financing investment in Amber Bio, a biotechnology company pioneering multi-kilobase gene editing platforms to reach previously undruggable diseases. Playground Global and Andreessen Horowitz Bio + Health led the financing with participation from Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC.
The funding will be used to advance a first-of-its-kind RNA editing platform which enables multi-kilobase edits, allowing a single drug to treat diseases with high allelic diversity. More information about Amber Bio’s $26 million seed financing can be obtained from the company’s press release.
The Fenwick transaction team was led by intellectual property partner Key Shin, counsel Amy Klann and associate Lucas Greder.